EXACT SCIENCES CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-11-01: Form 8-K; Period of report 2023-10-31; Description 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 2.02.
- 2023-08-01: Form 8-K; Period of report 2023-08-01; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2023-06-21: Form 8-K; Period of report 2023-06-21; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2023-06-12: Form 8-K; Period of report 2023-06-08; Description 3.03 Material Modification to Rights of Security Holders; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; Details 3.03.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2023-11-01 | 8-K | 2023-10-31 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On November 1, 2023, Exact Sciences Corporation (the "Company") announced its financial results for the quarter ended September 30, 2023. 5.02 On October 31, 2023, the Board of Directors (the “Board”) of the Company expanded the size of the Board from 10 to 11 members and appointed Timothy Scannell as a Class III member of the Board with a term ending at the Company’s 2024 annual meeting of shareholders. | exas-20231031.htm |
| 2023-08-01 | 8-K | 2023-08-01 | 2.02 Results of Operations and Financial Condition | 2.02 On August 1, 2023, Exact Sciences Corporation announced its financial results for the quarter ended June 30, 2023. | exas-20230801.htm |
| 2023-06-21 | 8-K | 2023-06-21 | 7.01 Regulation FD Disclosure | 7.01 Exact Sciences Corporation (the "Company") will host an Investor Day on June 21, 2023 beginning at 10:00 a.m. | exas-20230621.htm |
| 2023-06-12 | 8-K | 2023-06-08 | 3.03 Material Modification to Rights of Security Holders; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 3.03 The information set forth in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference. 5.02 On June 8, 2023, the shareholders of Exact Sciences Corporation (the “Company”) approved Amendment No. 2 (“Amendment No. 2”) to the Company’s 2019 Omnibus Long-Term Incentive Plan (the “2019 Plan”). 5.03 On June 9, 2023, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to its Sixth Amended and Restated Certificate of Incorporation, as amended with the Secretary of State of the State of Delaware effecting an amendment to declassify our Board of Directors over a three-year period. 5.07 On June 8, 2023, the Company held the 2023 Annual Meeting. | exas-20230608.htm |
| 2023-05-09 | 8-K | 2023-05-09 | 2.02 Results of Operations and Financial Condition | exas-20230509.htm | |
| 2023-03-17 | 8-K | 2023-03-17 | 8.01 Other Events | 8.01 On March 17, 2023, Exact Sciences Corporation (the “Company”) filed with the Securities and Exchange Commission, a prospectus supplement dated March 17, 2023 (the “Prospectus Supplement”) to the Company's automatic shelf registration statement on Form S-3 (Registration No. 333-238845). | exas-20230317.htm |
| 2023-03-03 | 8-K | 2023-03-02 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 2.03 On March 2, 2023, Exact Sciences Corporation (the “Company”) entered into privately negotiated exchange agreements (the “Agreements”) with two holders (the “Holders”) of the Company’s 1.00% Convertible Senior Notes due 2025 (the “2025 Notes”). 3.02 The information set forth in Item 2.03 of this Current Report on Form 8-K is incorporated herein by reference. | exas-20230302.htm |
| 2023-03-01 | 8-K | 2023-02-23 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 On March 1, 2023, Exact Sciences Corporation (the “Company”) completed the closing of the transactions contemplated by that certain Exchange and Purchase Agreement, dated February 23, 2023 (the “Agreement”), by and between the Company and a holder (the “Holder”) of certain of the Company’s 0.3750% Convertible Senior Notes due 2027 (the “Existing 2027 Notes”) and certain of the Company’s 0.3750% Convertible Senior Notes due 2028 (the “Existing 2028 Notes” and together with the Existing 2027 Notes, the “Existing Notes”). 2.03 The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. 3.02 The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. 8.01 The Company issued a press release dated February 23, 2023 announcing the Exchange and Purchase. | exas-20230223.htm |
| 2023-02-21 | 8-K | 2023-02-21 | 2.02 Results of Operations and Financial Condition | exas-20230221.htm | |
| 2023-01-09 | 8-K | 2023-01-08 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | exas-20230108.htm |